<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: clinical trials may", fill: "#80461b"},
{source: "1: clinical trials may", target: "1: candidates", fill: "#80461b"},
{source: "1: candidates", target: "1: in the United States or Europe ", fill: "#80461b"},
{source: "1: in the United States or Europe ", target: "1: timely basis", fill: "#80461b"},
{source: "1: clinical trials may", target: "2: drug candidates", fill: "#ab4e52"},
{source: "2: drug candidates", target: "2: government regulations", fill: "#ab4e52"},
{source: "2: government regulations", target: "2: development", fill: "#ab4e52"},
{source: "2: development", target: "2: manufacturing", fill: "#ab4e52"},
{source: "2: manufacturing", target: "2: commercialization", fill: "#ab4e52"},
{source: "2: drug candidates", target: "5: regulatory", fill: "#6c541e"},
{source: "5: regulatory", target: "5: unanticipated", fill: "#6c541e"},
{source: "5: regulatory", target: "29: development", fill: "#cba135"},
{source: "29: development", target: "29: technologies", fill: "#cba135"},
{source: "29: technologies", target: "29: therapeutic", fill: "#cba135"},
{source: "29: development", target: "95: recently raised net proceeds", fill: "#6495ed"},
{source: "95: recently raised net proceeds", target: "95: common stock", fill: "#6495ed"},
{source: "95: common stock", target: "95: actual costs", fill: "#6495ed"},
{source: "95: actual costs", target: "95: current cash resources", fill: "#6495ed"},
{source: "95: recently raised net proceeds", target: "START_HERE", fill: "#6495ed"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LA JOLLA PHARMACEUTICAL CO      Item 1A <font color="blue">Risk Factors     </font>I Risk Factors Relating To La Jolla Pharmaceutical Company And The Industry     In Which We Operate     Results from our <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> may</font> not be sufficient to obtain approval to     market Riquent or our other drug <font color="blue">candidates</font> <font color="blue">in the <font color="blue">United States </font>or Europe     </font>on a <font color="blue">timely basis</font>, or at all</td>
    </tr>
    <tr>
      <td>Our drug <font color="blue">candidates</font> are subject to extensive <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font>     related   to   <font color="blue">development</font>,   clinical   trials,   <font color="blue">manufacturing</font>   and     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In order to sell any product that is under <font color="blue">development</font>,     we must first receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>To obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, we     <font color="blue">must conduct <font color="blue"><font color="blue">clinical trial</font>s</font></font> and <font color="blue">toxicology studies</font> that <font color="blue">demonstrate</font> that     our drug <font color="blue">candidates</font> are safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>The process of obtaining FDA and     other <font color="blue"><font color="blue">regulatory</font> approval</font>s is costly, time consuming, uncertain and subject     to <font color="blue">unanticipated</font> delays</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> have substantial <font color="blue">discretion</font>     in the <font color="blue">approval process</font> and may not agree that we have <font color="blue">demonstrate</font>d that     Riquent is safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Riquent </font>is ultimately not found to be safe     and  <font color="blue">effective</font>,  we  would  be unable to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to     <font color="blue">manufacture</font>,  market  and  sell  Riquent</td>
    </tr>
    <tr>
      <td>Although we have received an     <font color="blue">approvable letter from</font> the FDA, the analysis of the data from our Phase 3     trial <font color="blue">of Riquent </font>showed that the                                         29       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>trial did not <font color="blue">reach statistical significance <font color="blue">with respect</font></font> to its primary     endpoint, time to <font color="blue">renal flare</font>, or <font color="blue">with respect</font> to its <font color="blue">secondary endpoint</font>,     time to <font color="blue">treatment with</font> high-dose corticosteroids or <font color="blue">cyclophosphamide</font></td>
    </tr>
    <tr>
      <td>We can     <font color="blue">provide no assurances</font> that the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> will     ultimately approve Riquent or, if approved, what the <font color="blue">indication</font> for <font color="blue"><font color="blue">Riquent  </font>   </font>will be</td>
    </tr>
    <tr>
      <td>Because Riquent is our only <font color="blue">drug candidate</font> for which we have completed     a Phase 3 <font color="blue">clinical trial</font>, and because there is no guarantee that we would be     able  to  develop an <font color="blue">alternate <font color="blue">drug candidate</font></font>, our <font color="blue">inability</font> to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">of Riquent </font>would have a <font color="blue">severe negative</font> effect on our     business, and, in the future, we may not have the <font color="blue">financial resources</font> to     <font color="blue">continue research</font> and <font color="blue">development</font> <font color="blue">of Riquent </font>or any other <font color="blue">potential drug</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In order to complete our <font color="blue">ongoing <font color="blue">clinical trial</font></font> of Riquent, we will need to     enroll a sufficient number of patients who meet the <font color="blue">trial criteria</font></td>
    </tr>
    <tr>
      <td>If we     are  unable  to  <font color="blue">successfully</font> complete the trial, our business will be     <font color="blue">adversely affected</font> and it may be <font color="blue">difficult</font> or impossible for us to continue     to operate</td>
    </tr>
    <tr>
      <td>We expect that the ongoing Phase 3 <font color="blue">clinical benefit trial</font> of <font color="blue"><font color="blue">Riquent  </font>   </font>will involve <font color="blue">approximately</font> 600 patients, which is <font color="blue"><font color="blue">significant</font>ly</font> more than     were involved in our previous Phase 3 trial</td>
    </tr>
    <tr>
      <td>We may have <font color="blue">difficult</font>y enrolling patients     because,  among  other  matters, there are <font color="blue">specific limitations on</font> the     <font color="blue">medications</font> that a <font color="blue">patient may</font> be taking <font color="blue">upon entry into</font> the trial</td>
    </tr>
    <tr>
      <td>If we     are unable to <font color="blue">timely enroll</font> a sufficient number of patients, we will not be     able to complete <font color="blue">successfully</font> the <font color="blue">ongoing trial</font></td>
    </tr>
    <tr>
      <td>As a result, it may be     <font color="blue">difficult</font> or impossible for us to continue to operate</td>
    </tr>
    <tr>
      <td>Current and <font color="blue">future clinical</font> trials of Riquent, trials of drugs related     to Riquent, or <font color="blue"><font color="blue">clinical trial</font>s</font> of other drug <font color="blue">candidates</font> may be delayed or     halted</td>
    </tr>
    <tr>
      <td>For example, in 2005, we limited <font color="blue">patient <font color="blue">enrollment</font></font> in our ongoing     <font color="blue">clinical benefit trial</font> in an effort to <font color="blue">reduce costs</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Phase     </font>2/3  clinical  trial  <font color="blue">of Riquent </font>was terminated before planned patient     <font color="blue">enrollment</font> was completed</td>
    </tr>
    <tr>
      <td>Current and future <font color="blue">trials may</font> be delayed or halted     for various reasons, including:       •   supplies of drug product are not sufficient to treat the patients in     the studies;       •   patients do not enroll in the <font color="blue">studies at</font> the rate we expect;       •   insufficient <font color="blue">financial resources</font>;       •   the products are not <font color="blue">effective</font>;       •   patients experience negative side effects or other <font color="blue">safety concerns</font> are     <font color="blue">raised during treatment</font>;       •   the trials are not conducted in <font color="blue"><font color="blue">accordance</font> with applicable clinical</font>     practices; or       •   the impact of <font color="blue">political unrest</font> or <font color="blue"><font color="blue">natural disaster</font>s at foreign</font>     <font color="blue">clinical sites</font></td>
    </tr>
    <tr>
      <td>If any current or future trials are delayed or halted, we may incur     <font color="blue">significant</font> <font color="blue">additional</font> expenses, and our potential approval <font color="blue">of Riquent </font>may     be delayed, which could have a <font color="blue">severe negative</font> effect on our business</td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font>We may be required to design and conduct <font color="blue">additional</font> trials</td>
    </tr>
    <tr>
      <td>We may be required to design and conduct <font color="blue">additional</font> studies to further     <font color="blue">demonstrate</font> the safety and efficacy of our drug <font color="blue">candidates</font>, which may result     in <font color="blue">significant</font> expense and delay</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>     may  require new or <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> because of <font color="blue">inconclusive</font>     results from current or earlier <font color="blue"><font color="blue">clinical trial</font>s</font> (including the Phase 2/3 and     Phase 3 trials of Riquent), a possible failure to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> in     complete adherence to FDA good <font color="blue">clinical practice standards</font> and similar     standards of foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>, the <font color="blue">identification</font> of new     <font color="blue"><font color="blue">clinical trial</font> endpoints</font>, or the need for <font color="blue">additional</font> data regarding the     safety or efficacy of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>It is possible that the FDA or     foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> may not ultimately approve Riquent or our     other drug <font color="blue">candidates</font> for <font color="blue">commercial sale</font> in any jurisdiction, even if we     believe <font color="blue">future clinical</font> results are positive</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">technology</font> underlying</font> our products is uncertain and unproven</td>
    </tr>
    <tr>
      <td>All  of  our  product  <font color="blue">development</font>  efforts are based on unproven     <font color="blue">technologies</font> and <font color="blue">therapeutic</font> approaches that have not been widely tested or     used</td>
    </tr>
    <tr>
      <td>To date, no products that use our <font color="blue">technology</font> have <font color="blue">been <font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>The  FDA has not determined that we have proven Riquent to be safe and     <font color="blue">effective</font> in humans, and the <font color="blue">technology</font> on which it is based has been used     only in our pre-clinical tests and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Application </font>of our     <font color="blue">technology</font> to antibody-mediated diseases other than lupus is in earlier     research stages</td>
    </tr>
    <tr>
      <td>Clinical trials <font color="blue">of Riquent </font>may be viewed as a test of our     <font color="blue">entire approach</font> to developing therapies for antibody-mediated diseases</td>
    </tr>
    <tr>
      <td>If     Riquent does not work as intended, or if the data from our <font color="blue"><font color="blue">clinical trial</font>s</font>     indicates that Riquent is not safe and <font color="blue">effective</font>, the <font color="blue">applicability</font> of our     <font color="blue">technology</font> for <font color="blue">successfully</font> treating antibody-mediated diseases will be     highly  uncertain</td>
    </tr>
    <tr>
      <td>As  a result, there is a <font color="blue">significant</font> risk that our     <font color="blue">therapeutic</font> approaches will not prove to be successful, and there can be no     guarantee  that  our  drug  <font color="blue">discovery</font>  <font color="blue">technologies</font> will result in any     <font color="blue"><font color="blue">commercially</font> successful products</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">implementing</font> a <font color="blue">commercial scale</font> <font color="blue">manufacturing</font> process for Riquent,     but we have not yet <font color="blue">manufacture</font>d an entire lot <font color="blue">of Riquent </font>at this commercial     scale</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">manufacture</font> Riquent in <font color="blue">accordance</font> with applicable     FDA good <font color="blue">manufacturing</font> practices at this <font color="blue">commercial scale</font>, our ability to     timely complete <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">of Riquent </font>will be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>If  we <font color="blue">encounter delays</font> or <font color="blue">difficult</font>ies in <font color="blue">establishing</font> or maintaining     relationships with <font color="blue">manufacturing</font> or <font color="blue"><font color="blue">distribution</font> <font color="blue">contractors</font></font>, our ability to     timely complete <font color="blue">necessary</font> <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">potentially</font> deliver commercial     <font color="blue">products may</font> be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>We may <font color="blue">enter into</font> <font color="blue"><font color="blue">arrangement</font>s</font> with contract <font color="blue">manufacturing</font> companies to     expand our own <font color="blue">production capacity</font> in order to meet demand for our products     or to attempt to improve <font color="blue">manufacturing</font> efficiency</td>
    </tr>
    <tr>
      <td>If we choose to contract     for <font color="blue">manufacturing</font> services, the FDA and comparable foreign <font color="blue">regulators</font> would     have to approve the contract <font color="blue">manufacture</font>rs prior to our use, and these     <font color="blue">contractors</font> would be required to <font color="blue">comply with</font> strictly enforced <font color="blue">manufacturing</font>     standards</td>
    </tr>
    <tr>
      <td>We may also <font color="blue">enter into</font> agreements with <font color="blue">contractors</font> to prepare and     distribute our drug <font color="blue">candidates</font> for <font color="blue">use by patients</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> or     <font color="blue">commercially</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter delays</font> or <font color="blue">difficult</font>ies in <font color="blue">establishing</font> or     maintaining relationships with <font color="blue">contractors</font> to produce, package or distribute     our drug <font color="blue">candidates</font>, if they are unable to meet our needs, if they are not     approved  by  the <font color="blue">regulatory</font> <font color="blue">authorities</font>, or if they fail to adhere to     applicable <font color="blue">manufacturing</font> standards, our ability to timely complete <font color="blue">necessary</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> and to introduce our <font color="blue">products into</font> the <font color="blue">market would</font> be     <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [85]Table of <font color="blue">Contents       </font>Our  limited <font color="blue">manufacturing</font> <font color="blue">capabilities</font> and experience could result in     shortages of drugs for future sale, and our revenues and <font color="blue">profit margin could</font>     be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>We have never operated a commercial <font color="blue">manufacturing</font> <font color="blue">facility</font> and we will     be  required  to  <font color="blue">manufacture</font>  Riquent pursuant to applicable FDA good     <font color="blue">manufacturing</font> practices</td>
    </tr>
    <tr>
      <td>Our inexperience could result in <font color="blue">manufacturing</font>     delays  or  <font color="blue"><font color="blue">interruption</font>s</font>  and  higher <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>This could     <font color="blue">negatively</font>  affect  our  ability  to supply the <font color="blue">market on</font> a timely and     <font color="blue"><font color="blue">competitive</font> basis</font></td>
    </tr>
    <tr>
      <td>The sales of our products, if any, and our <font color="blue">profit margins</font>     may also be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition, substantial <font color="blue">capital <font color="blue">investment</font></font>     in the expansion and build-out of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> and/or the     <font color="blue">engagement</font> of <font color="blue">third party</font> contract <font color="blue">manufacture</font>rs will be required to enable     us to <font color="blue">manufacture</font> Riquent, if approved, in <font color="blue">sufficient commercial quantities</font></td>
    </tr>
    <tr>
      <td>We  have  limited  <font color="blue">manufacturing</font>  experience,  and we may be unable to     <font color="blue">successfully</font> transition to <font color="blue">commercial production</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">suppliers may</font> not be able to <font color="blue"><font color="blue">provide us</font> with <font color="blue">sufficient quantities</font></font> of     materials that we may need to <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on outside suppliers</font> to <font color="blue"><font color="blue">provide us</font> with specialized <font color="blue">chemicals</font></font>     and reagents that we use to <font color="blue">manufacture</font> our drugs</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">manufacture</font>     Riquent and our other drug <font color="blue">candidates</font> in <font color="blue">sufficient quantities</font> for our     clinical  trials and possible <font color="blue">commercialization</font>, our suppliers will be     required to <font color="blue">provide us</font> with an adequate supply of <font color="blue">chemicals</font> and reagents</td>
    </tr>
    <tr>
      <td>Our  ability  to obtain these <font color="blue">chemicals</font> and reagents is subject to the     <font color="blue">following risks</font>:       •   our <font color="blue">suppliers may</font> not be able to increase their own <font color="blue">manufacturing</font>     <font color="blue">capabilities</font> in order to <font color="blue">provide us</font> with a <font color="blue">sufficient amount</font> of material for     our use;       •   some of our <font color="blue">suppliers may</font> be required to pass FDA <font color="blue">inspections</font> or     <font color="blue"><font color="blue">validation</font>s</font> or to obtain other <font color="blue"><font color="blue">regulatory</font> approval</font>s of their <font color="blue">manufacturing</font>     <font color="blue">facilities</font> or processes, and they may be delayed or unable to do so;       •   the materials that our <font color="blue">suppliers use</font> to <font color="blue">manufacture</font> the <font color="blue">chemicals</font> and     reagents that they <font color="blue">provide us</font> may be costly or in short supply; and       •   there are a limited number of suppliers that are able to <font color="blue">provide us</font>     with the <font color="blue">chemicals</font> or reagents that we use to <font color="blue">manufacture</font> our drugs</td>
    </tr>
    <tr>
      <td>If  we are unable to obtain <font color="blue">sufficient quantities</font> of <font color="blue">chemicals</font> or     reagents,  our  ability  to produce products for <font color="blue">clinical studies</font> and,     therefore, to introduce <font color="blue">products into</font> the <font color="blue">market on</font> a timely and <font color="blue">competitive</font>     basis, will be impeded</td>
    </tr>
    <tr>
      <td>The <font color="blue">subsequent sales</font> of our products, if any, and     our <font color="blue">profit margins</font> may also be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> in the operation of our sole <font color="blue">manufacturing</font> <font color="blue">facility</font> could     disrupt our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  have  only  one  drug  <font color="blue">manufacturing</font>  <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font>     <font color="blue">interruption</font> in the operation of this <font color="blue">facility</font>, whether as a result of a     <font color="blue">natural disaster</font> or other causes, could <font color="blue"><font color="blue">significant</font>ly</font> impair our ability to     <font color="blue">manufacture</font> drugs for our <font color="blue"><font color="blue">clinical trial</font>s</font> or possible <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>32       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font>If we are to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of Riquent, we must validate our     <font color="blue">manufacturing</font> <font color="blue">facilities</font> and processes</td>
    </tr>
    <tr>
      <td>Although a successful pre-approval inspection was conducted by the FDA     in July 2004, we have never operated a commercial <font color="blue">manufacturing</font> <font color="blue">facility</font> and     we have not yet completed the <font color="blue">validation</font> of our <font color="blue">manufacturing</font> processes</td>
    </tr>
    <tr>
      <td>If     we  are  unable  to maintain <font color="blue">validated conditions at</font> our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> or fail to <font color="blue">successfully</font> validate our <font color="blue">manufacturing</font> processes to     the  <font color="blue">satisfaction</font> of the <font color="blue">regulatory</font> <font color="blue">authorities</font>, they will not approve     Riquent for commercial use</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently devoting nearly</font> all of our resources to the <font color="blue">development</font> and     approval of Riquent</td>
    </tr>
    <tr>
      <td>Accordingly, our efforts <font color="blue">with respect</font> to other drug     <font color="blue">candidates</font> have <font color="blue"><font color="blue">significant</font>ly</font> diminished</td>
    </tr>
    <tr>
      <td>We have <font color="blue">currently budgeted only</font> a limited amount of funds for the     <font color="blue">development</font> of small molecules for the treatment of <font color="blue">autoimmune diseases</font> and     acute and <font color="blue">chronic inflammatory disorders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font>future <font color="blue">development</font> of     these  drug <font color="blue">candidates</font> may depend on our ability to obtain <font color="blue">third party</font>     financing for this program</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">significant</font> progress <font color="blue">with respect</font>     to drug <font color="blue">candidates</font> other than Riquent, if any, will be <font color="blue"><font color="blue">significant</font>ly</font> delayed     and our success and ability to continue to operate <font color="blue">depends on whether</font> we     obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to market Riquent</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> depend on key employees</td>
    </tr>
    <tr>
      <td>Losing these <font color="blue">employees would</font> have a     negative effect on our product <font color="blue">development</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly <font color="blue">dependent on</font></font> the <font color="blue">principal members</font> of our scientific and     <font color="blue"><font color="blue">management</font> staff</font>, the loss of <font color="blue">whose services would delay</font> the <font color="blue">achievement</font> of     our research and <font color="blue">development</font> objectives</td>
    </tr>
    <tr>
      <td>This is because our <font color="blue">key personnel</font>,     including Steven Engle, Dr</td>
    </tr>
    <tr>
      <td>Matthew Linnik, Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Paul Jenn and Dr</font></td>
    </tr>
    <tr>
      <td>Andrew     Wiseman, have <font color="blue">been involved</font> in the <font color="blue">development</font> <font color="blue">of Riquent </font>and other drug     <font color="blue">candidates</font>  for  several  years  and have <font color="blue">unique knowledge</font> of our drug     <font color="blue">candidates</font> and of the <font color="blue">technology</font> on which they are based</td>
    </tr>
    <tr>
      <td>In addition, we     will be required to rely on other key members of our <font color="blue">senior <font color="blue">management</font> team</font>     to <font color="blue">assist us</font> with, among other matters, clinical <font color="blue">development</font>, <font color="blue">manufacturing</font>,     <font color="blue">regulatory</font>, business <font color="blue">development</font> and potential <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Retaining </font>our <font color="blue">current personnel</font> and recruiting <font color="blue">additional</font> personnel will be     critical to our success</td>
    </tr>
    <tr>
      <td><font color="blue">Retaining </font>our current <font color="blue">key personnel</font> to perform clinical <font color="blue">development</font>,     <font color="blue">manufacturing</font>,  <font color="blue">regulatory</font>,  research  and  <font color="blue">development</font>,  and business     <font color="blue">development</font> <font color="blue">activities</font> will be critical to our near <font color="blue">term success</font></td>
    </tr>
    <tr>
      <td>We expect     that  recruiting  <font color="blue">additional</font>  qualified  personnel to <font color="blue">conduct clinical</font>     <font color="blue">development</font>, <font color="blue">manufacturing</font>, <font color="blue">regulatory</font>, research and <font color="blue">development</font>, business     <font color="blue">development</font>,  and  marketing  and <font color="blue">sales <font color="blue">activities</font> will</font> be required to     <font color="blue">successfully</font> further develop Riquent and any <font color="blue">additional</font> drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">competition</font> for experienced clinical, <font color="blue">manufacturing</font>, <font color="blue">regulatory</font>,     scientific, business <font color="blue">development</font>, and marketing and <font color="blue">sales personnel among</font>     numerous  <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> companies and research and     <font color="blue">academic <font color="blue">institutions</font></font> is intense, we may not be able to attract and retain     these people</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot attract</font> and retain qualified people, our ability     to  conduct  <font color="blue">necessary</font>  <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">manufacture</font> drug, <font color="blue">comply with</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font>, <font color="blue">enter into</font> <font color="blue">collaborative</font> agreements and develop and     sell potential <font color="blue">products may</font> be <font color="blue"><font color="blue">negatively</font> affected</font> because, for instance,     the <font color="blue">trials may</font> not be <font color="blue">conducted properly</font>, or the                                         33       _________________________________________________________________    [87]Table of <font color="blue">Contents       </font><font color="blue">manufacturing</font> or sales of our <font color="blue">products may</font> be delayed</td>
    </tr>
    <tr>
      <td>In addition, we rely     on  <font color="blue">consultants</font> and advisors to <font color="blue">assist us</font> in <font color="blue">formulating</font> our clinical,     <font color="blue">manufacturing</font>, <font color="blue">regulatory</font>, research and <font color="blue">development</font>, business <font color="blue">development</font>,     and marketing and <font color="blue">sales strategies</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">consultants</font> and advisors have     outside  <font color="blue">employment</font> and may have <font color="blue">commitments</font> or consulting or advisory     contracts with other entities that may limit their ability to contribute to     our business</td>
    </tr>
    <tr>
      <td>Our efforts to obtain approval to market <font color="blue">Riquent in Europe </font>may be delayed or     <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>In order to obtain approval to market Riquent in Europe, we must submit     an MAA to and pass <font color="blue">inspections</font> of the European <font color="blue">health authority</font></td>
    </tr>
    <tr>
      <td>Ultimately,     a  <font color="blue">representative</font> from each of the European Member States <font color="blue">will vote on</font>     whether to approve the MAA Upon receiving the MAA, we expect that the     Committee for Human Medicinal Products, a division of the EMEA, <font color="blue">will review</font>     the MAA and respond to us with a number of questions</td>
    </tr>
    <tr>
      <td>The <font color="blue">approval process</font>     may be delayed because, among other matters: the answers to the questions     posed by the EMEA may require <font color="blue">additional</font> tests to be conducted to obtain the     answers to the <font color="blue">questions posed</font>; we, or one of our contract <font color="blue">manufacturing</font>     <font color="blue">facilities</font>, may be unable to <font color="blue">successfully</font> pass an <font color="blue">inspection by</font> the European     <font color="blue">health authority</font>; or the European <font color="blue">health authority</font> ultimately may not accept     the  data  presented  in the MAA in <font color="blue">combination</font> with our proposals for     post-authorization <font color="blue">commitments</font> as adequate for approval under <font color="blue">the EMEA     </font>“exceptional  <font color="blue">circumstances</font>” regulation</td>
    </tr>
    <tr>
      <td>The exceptional <font color="blue">circumstances</font>     regulation is a path to approval in Europe that may be available when the     <font color="blue">comprehensive <font color="blue">assessment</font></font> of a product’s efficacy or safety is not possible     at the time of filing because of the rarity of the <font color="blue">indication</font>, the state of     scientific  knowledge, or the means <font color="blue">by which such</font> information would be     gathered is contrary to <font color="blue">medical ethics</font></td>
    </tr>
    <tr>
      <td>In addition, we must <font color="blue">manufacture</font>     <font color="blue">three consecutive lots</font> <font color="blue">of Riquent </font>to validate our <font color="blue">manufacturing</font> process as     part of our MAA If we encounter <font color="blue">difficult</font>ies in <font color="blue">successfully</font> completing     this component of the MAA, our <font color="blue">application will</font> not be complete and approval     will  not  be granted</td>
    </tr>
    <tr>
      <td>Even if we receive approval in Europe under the     exceptional  <font color="blue"><font color="blue">circumstances</font> regulation</font>, we will be required to complete     several post-authorization <font color="blue">commitments</font>, including a long-term clinical     <font color="blue">efficacy study</font>, the progress of <font color="blue">which will</font> be <font color="blue">reviewed frequently by</font> the     European health <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> complete these     <font color="blue">activities</font> to the <font color="blue">satisfaction</font> of the European health <font color="blue">authorities</font>, our     license to market Riquent in Europe, if any, could be revoked</td>
    </tr>
    <tr>
      <td>We may not have sufficient <font color="blue">financial resources</font> to complete the ongoing <font color="blue">Phase     </font>3 <font color="blue">clinical benefit trial</font> of Riquent</td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">successfully</font> complete the ongoing Phase 3 clinical     <font color="blue">benefit study</font> <font color="blue">of Riquent </font>prior to FDA approval</td>
    </tr>
    <tr>
      <td>We expect that the ongoing     Phase 3 <font color="blue">clinical benefit trial</font> will involve <font color="blue">approximately</font> 600 patients and     take <font color="blue">several years</font> to complete</td>
    </tr>
    <tr>
      <td>Although we <font color="blue"><font color="blue">recently raised</font> net proceeds</font> of     <font color="blue">approximately</font> dlra62dtta3 million from the sale of <font color="blue">common stock</font> and warrants, the     <font color="blue">actual costs</font> of completing the ongoing Phase 3 <font color="blue">clinical benefit trial</font> of     Riquent may exceed our <font color="blue">current cash resources</font></td>
    </tr>
    <tr>
      <td>In that case, if we expend     all of the funds that we <font color="blue">recently raised</font> and do not receive <font color="blue">funding from</font> a     <font color="blue"><font color="blue">collaborative</font> agreement with</font> a <font color="blue">corporate partner</font> or obtain other financing,     we would not have the <font color="blue">financial resources</font> to complete the ongoing Phase 3     clinical  benefit trial or to continue the research and <font color="blue">development</font> of     Riquent, and it would be <font color="blue">difficult</font> or impossible for us to continue to     operate</td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> funds to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have consumed substantial <font color="blue">capital resources</font></td>
    </tr>
    <tr>
      <td>Before we can obtain FDA approval for Riquent, we will need to                                         34       _________________________________________________________________    [88]Table of <font color="blue">Contents       </font><font color="blue">successfully</font>  complete  the ongoing Phase 3 <font color="blue">clinical benefit trial</font> and     possibly <font color="blue">additional</font> trials</td>
    </tr>
    <tr>
      <td>Therefore, we expect to expend substantial     amounts of <font color="blue">capital resources</font> for <font color="blue">additional</font> research, product <font color="blue">development</font>,     pre-clinical testing and <font color="blue"><font color="blue">clinical trial</font>s</font> of Riquent</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also devote</font>     substantial <font color="blue">additional</font> <font color="blue">capital resources</font> to establish commercial-scale     <font color="blue">manufacturing</font> <font color="blue">capabilities</font> and to market and <font color="blue">sell <font color="blue">potential products</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">expenses may</font> be <font color="blue">incurred prior</font> to or after any <font color="blue"><font color="blue">regulatory</font> approval</font>s that we     may receive</td>
    </tr>
    <tr>
      <td>Even with the net proceeds of <font color="blue">approximately</font> dlra62dtta3 million from     our  recent  stock  and <font color="blue">warrant offering</font>, we expect that we would need     <font color="blue">additional</font>  funds to finance our future <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital</font>     <font color="blue"><font color="blue">requirements</font> <font color="blue">will depend on</font></font> many factors, including:       •   the scope and results of our <font color="blue"><font color="blue">clinical trial</font>s</font>;       •   our ability to <font color="blue">manufacture</font> <font color="blue">sufficient quantities</font> of drug to support     <font color="blue"><font color="blue">clinical trial</font>s</font>;       •   our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for Riquent;       •   the time and costs involved in applying for <font color="blue"><font color="blue">regulatory</font> approval</font>s;       •   continued scientific progress in our research and <font color="blue">development</font>     programs;       •   the size and <font color="blue">complexity</font> of our research and <font color="blue">development</font> programs;       •   the costs involved in preparing, filing, prosecuting, maintaining and     enforcing patent claims;       •   competing <font color="blue">technological</font> and market <font color="blue">development</font>s;       •   our ability to establish and maintain <font color="blue">collaborative</font> research and     <font color="blue">development</font> <font color="blue"><font color="blue">arrangement</font>s</font>;       •   our need to establish commercial <font color="blue">manufacturing</font> <font color="blue">capabilities</font>; and       •   our ability to develop <font color="blue">effective</font> marketing and sales programs</td>
    </tr>
    <tr>
      <td>We expect to incur substantial <font color="blue">losses each year</font> for at least the next     <font color="blue">several years</font> as we continue our planned <font color="blue">clinical trial</font>, <font color="blue">manufacturing</font>,     <font color="blue">regulatory</font>,  and research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we ultimately     receive  <font color="blue">regulatory</font>  approval  for  Riquent,  or any of our other drug     <font color="blue">candidates</font>, our <font color="blue">manufacturing</font>, marketing and sales <font color="blue">activities</font> are likely to     <font color="blue">substantially increase</font> our expenses and our need for <font color="blue">additional</font> working     capital</td>
    </tr>
    <tr>
      <td>In the future, it is possible that we will not have adequate     resources to support <font color="blue">continuation</font> of our business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We may need to sell stock or assets, <font color="blue">enter into</font> <font color="blue">collaborative</font> agreements,     <font color="blue"><font color="blue">significant</font>ly</font>  reduce  our <font color="blue">operations</font>, or <font color="blue">merge with</font> another entity to     continue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business is highly cash-intensive and we expect that we will need a     <font color="blue">significant</font> amount of <font color="blue">additional</font> cash to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There can     be  no  guarantee that <font color="blue">additional</font> financing will be available to us on     favorable  terms,  or  at  all, <font color="blue">whether through issuance</font> of <font color="blue">additional</font>     securities, entry into <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>, or otherwise</td>
    </tr>
    <tr>
      <td>If adequate     funds are not available, we may delay, scale back or <font color="blue">eliminate one</font> or more     of our research and                                         35       _________________________________________________________________    [89]Table of <font color="blue">Contents       </font><font color="blue">development</font> programs, which may include delaying or halting the ongoing     Phase 3 <font color="blue">clinical benefit trial</font> of Riquent, reduce the size of our workforce,     sell or license our <font color="blue">technologies</font> or obtain <font color="blue">funds through</font> other <font color="blue"><font color="blue">arrangement</font>s</font>     with <font color="blue">collaborative</font> partners or others that require us to <font color="blue">relinquish rights</font>     to our <font color="blue">technologies</font> or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We also may <font color="blue">merge with</font> another     entity to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any one of these <font color="blue">outcomes could</font> have a     <font color="blue">negative impact on</font> our ability to develop products or achieve <font color="blue">profitability</font>     if our products are brought to market</td>
    </tr>
    <tr>
      <td>If, and to the extent, we obtain     <font color="blue">additional</font> funding through sales of securities, any <font color="blue">investment</font> in us will be     diluted, and dilution can be <font color="blue">particularly</font> substantial when the price of our     <font color="blue">common stock</font> is low</td>
    </tr>
    <tr>
      <td>Our  freedom to operate our business or <font color="blue">profit fully from sales</font> of our     <font color="blue">products may</font> be limited if we <font color="blue">enter into</font> <font color="blue">collaborative</font> agreements</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">collaborate with</font> other <font color="blue">pharmaceutical</font> companies to gain     access to their financial, research, drug <font color="blue">development</font>, <font color="blue">manufacturing</font>, or     marketing and <font color="blue">sales resources</font></td>
    </tr>
    <tr>
      <td>However, we may not be able to negotiate     <font color="blue"><font color="blue">arrangement</font>s</font> with any <font color="blue">collaborative</font> partners on favorable terms, if at all</td>
    </tr>
    <tr>
      <td>Any <font color="blue">collaborative</font> relationships that we <font color="blue"><font color="blue">enter into</font> may</font> include <font color="blue">restrictions</font>     on  our freedom to operate our business or may limit our <font color="blue">revenues from</font>     <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">collaborative</font> <font color="blue">arrangement</font> is established, the     <font color="blue">collaborative</font> partner may <font color="blue">discontinue</font> funding any particular program or may,     either alone or with others, pursue <font color="blue">alternative</font> <font color="blue">technologies</font> or develop     <font color="blue">alternative</font> drug <font color="blue">candidates</font> for the diseases we are targeting</td>
    </tr>
    <tr>
      <td><font color="blue">Competing     </font>products, developed by a <font color="blue">collaborative</font> partner or to which a <font color="blue">collaborative</font>     partner has rights, may result in the <font color="blue">collaborative</font> partner withdrawing     <font color="blue">support as</font> to all or a portion of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Without <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>, we must fund our own research,     <font color="blue">development</font>,  <font color="blue">manufacturing</font>, and marketing and sales <font color="blue">activities</font>, which     <font color="blue">accelerates</font> the depletion of our cash and requires us to develop our own     <font color="blue">manufacturing</font> and marketing and sales <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Therefore, if the costs     of completing the ongoing <font color="blue">clinical benefit trial</font> <font color="blue">of Riquent </font><font color="blue"><font color="blue">significant</font>ly</font>     exceed  our  estimates  and  we  are  unable to establish and maintain     <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> and if other sources of cash are not available,     we could experience a material adverse effect on our ability to develop     products and, if developed and approved, to <font color="blue">manufacture</font>, market and sell     them <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">blood test</font> to measure the <font color="blue">binding <font color="blue">affinity</font></font> <font color="blue">for Riquent </font>has not been     <font color="blue">validated by independent <font color="blue">laboratories</font></font> and is likely to require <font color="blue">regulatory</font>     review as part of the Riquent <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>In 1998, we developed a <font color="blue">blood test</font> that we believe can identify the     <font color="blue">lupus patients</font> who are <font color="blue">most likely</font> to respond to Riquent</td>
    </tr>
    <tr>
      <td>The <font color="blue">blood test</font> is     designed  to measure the strength of the <font color="blue">binding between</font> Riquent and a     patient’s  <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>This  <font color="blue">affinity</font>  assay  was  used  to identify,     <font color="blue">prospectively</font> in the Phase 3 trial and <font color="blue">retrospectively</font> in the Phase 2/3     trial,  the  patients  included  in the <font color="blue">efficacy analyses</font></td>
    </tr>
    <tr>
      <td><font color="blue">Independent     </font><font color="blue">laboratories</font> have not validated the assay, and the results of the <font color="blue">affinity</font>     assay observed in our <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">of Riquent </font>may not be observed in the     <font color="blue">broader lupus patient population</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although the FDA </font>has reviewed the blood     assay as part of the <font color="blue">approval process</font> of Riquent, the FDA’s review of the     <font color="blue">assay will</font> not be complete until after Riquent is approved, if ever, and we     and  the  FDA  agree  upon the label for Riquent</td>
    </tr>
    <tr>
      <td>In addition, foreign     <font color="blue">regulatory</font> <font color="blue">authorities</font> may require that the assay be <font color="blue">reviewed as</font> part of     their  <font color="blue">approval process</font> for Riquent</td>
    </tr>
    <tr>
      <td>Even if Riquent and the assay are     approved  by the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>, we may have to     conduct  <font color="blue">additional</font>  studies  on  the assay post-approval</td>
    </tr>
    <tr>
      <td>The testing     <font color="blue">laboratory</font> that <font color="blue">will conduct</font> the assay if Riquent is <font color="blue">approved may also</font>     require <font color="blue">additional</font> <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font> do not concur with the use of the                                         36       _________________________________________________________________    [90]Table of <font color="blue">Contents       </font>assay to identify <font color="blue">potential patients</font> for <font color="blue">treatment with</font> Riquent, or if any     of them requires <font color="blue">additional</font> studies on the assay or <font color="blue">additional</font> <font color="blue">regulatory</font>     approval   of  the  testing  <font color="blue">laboratory</font>,  the  approval  and  possible     <font color="blue">commercialization</font> <font color="blue">of Riquent </font>may be delayed or prevented, which would have a     <font color="blue">severe negative</font> effect on our business</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">regulatory</font> approval</font>s that we may obtain for our product <font color="blue">candidates</font> may     be limited and <font color="blue"><font color="blue">subsequent issue</font>s</font> regarding safety or <font color="blue">efficacy could</font> cause us     to <font color="blue">remove products from</font> the market</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> grant approval of any of     our drug <font color="blue">candidates</font>, the <font color="blue">approval may</font> be limited to <font color="blue">specific conditions</font> or     <font color="blue">patient populations</font>, or limited <font color="blue">with respect</font> to its <font color="blue">distribution</font>, including     to specified <font color="blue">facilities</font> or <font color="blue">physicians with special training</font> or experience</td>
    </tr>
    <tr>
      <td>The imposition of any of these <font color="blue">restrictions</font> or other <font color="blue">restrictions</font> on the     marketing and use <font color="blue">of Riquent </font><font color="blue">could adversely affect</font> any <font color="blue">future sales</font> of     Riquent</td>
    </tr>
    <tr>
      <td>Furthermore, even if a <font color="blue">drug candidate</font> is approved, it is possible     that a <font color="blue">subsequent issue</font> regarding its safety or <font color="blue">efficacy would</font> require us to     remove the drug from the market</td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font> for our product <font color="blue">candidates</font>, we will     be subject to ongoing <font color="blue">regulatory</font> <font color="blue">obligations</font> and review</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>any <font color="blue"><font color="blue">regulatory</font> approval</font> of our product <font color="blue">candidates</font>, we will be     subject  to continuing <font color="blue">regulatory</font> <font color="blue">obligations</font> such as safety reporting     <font color="blue">requirements</font> and <font color="blue">additional</font> post-marketing <font color="blue">obligations</font>, including <font color="blue">regulatory</font>     oversight of the promotion and marketing of our products</td>
    </tr>
    <tr>
      <td>In addition, we,     and any third-party <font color="blue">manufacture</font>rs, will be required to adhere to <font color="blue">regulations</font>     <font color="blue">setting forth current</font> good <font color="blue">manufacturing</font> practices</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> cover     all  aspects of the <font color="blue">manufacturing</font>, testing, quality control and record     keeping  relating  to our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Furthermore, we, and any     third-party  <font color="blue">manufacture</font>rs,  will be subject to periodic <font color="blue">inspection by</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">inspections</font> may result in <font color="blue">compliance issues</font>     that  would  require the <font color="blue">expenditure</font> of <font color="blue">significant</font> financial or other     resources to address</td>
    </tr>
    <tr>
      <td>If we, or any third-party <font color="blue">manufacture</font>rs that we may     engage, fail to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, we may be     subject to fines, suspension or withdrawal of <font color="blue"><font color="blue">regulatory</font> approval</font>s, product     recalls,  seizure  of  products,  operating  <font color="blue">restrictions</font> and criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>The size of the market for our <font color="blue">potential products</font> is uncertain</td>
    </tr>
    <tr>
      <td>We estimate that the number of people who <font color="blue">suffer from lupus</font> in the     <font color="blue"><font color="blue">United States </font>and Europe </font>is <font color="blue">potentially</font> more than 1cmam000cmam000 and those with     renal impairment, which Riquent is designed to treat, is <font color="blue">approximately</font>     300cmam000</td>
    </tr>
    <tr>
      <td>However, there is limited information available regarding the     <font color="blue">actual size</font> of these <font color="blue">patient populations</font></td>
    </tr>
    <tr>
      <td>In addition, it is uncertain     whether the results <font color="blue">from previous</font> or <font color="blue">future clinical</font> trials of our drug     <font color="blue">candidates</font> will be observed in broader <font color="blue">patient populations</font>, and the number     of patients who <font color="blue">may <font color="blue">benefit from</font></font> our drug <font color="blue">candidates</font> may be <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">smaller than</font> the estimated <font color="blue">patient populations</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">management</font> of     <font color="blue">patients with renal disease by specialists</font> other <font color="blue">than nephrologists</font> and     <font color="blue">immunologists</font> is likely to reduce our ability to <font color="blue">access patients</font> who may     <font color="blue">benefit from</font> Riquent</td>
    </tr>
    <tr>
      <td>Our drugs may not achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Even  if  Riquent or our other drug <font color="blue">candidates</font> receive <font color="blue">regulatory</font>     approval, patients and <font color="blue">physicians may</font> not readily or quickly accept our     proposed  methods of treatment</td>
    </tr>
    <tr>
      <td>In order <font color="blue">for Riquent </font>or our other drug     <font color="blue">candidates</font> to be <font color="blue">commercially</font> successful, we will need to increase the                                         37       _________________________________________________________________    [91]Table of <font color="blue">Contents       </font>awareness and <font color="blue">acceptance</font> of our drug <font color="blue">candidates</font> among physicians, patients     and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Riquent is designed to be <font color="blue"><font color="blue">administered</font> weekly by</font>     <font color="blue">intravenous injection</font></td>
    </tr>
    <tr>
      <td>It is possible that providers and <font color="blue">patients may resist</font>     an  <font color="blue">intravenously</font>  <font color="blue">administered</font>  <font color="blue">therapeutic</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that     <font color="blue">physician treatment practices may</font> change and that the use of other drugs,     <font color="blue">either newly approved</font> or <font color="blue">currently on</font> the market for other conditions, may     <font color="blue">become widely utilized by clinicians</font> for the treatment of patients with     lupus and reduce the <font color="blue">potential use</font> <font color="blue">of Riquent </font>in this patient population</td>
    </tr>
    <tr>
      <td>In     addition, if we are unable to <font color="blue">manufacture</font> drugs at an acceptable cost,     <font color="blue">physicians may</font> not <font color="blue">readily prescribe drugs</font> that we may <font color="blue">manufacture</font> due to     cost-benefit considerations when compared to other methods of treatment</td>
    </tr>
    <tr>
      <td>If     we  are unable to achieve <font color="blue">market <font color="blue">acceptance</font></font> for <font color="blue">approved products</font>, our     revenues and potential for <font color="blue">profitability</font> will be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>We lack experience in <font color="blue">marketing products</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> any <font color="blue">drug candidate</font> <font color="blue">approved by</font> the FDA or     foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>, we must either develop marketing and sales     programs or <font color="blue">enter into</font> marketing <font color="blue"><font color="blue">arrangement</font>s</font> with others</td>
    </tr>
    <tr>
      <td>If we cannot do     either of these <font color="blue">successfully</font>, we will not <font color="blue">generate meaningful sales</font> of any     products that may be approved</td>
    </tr>
    <tr>
      <td>If we develop our own marketing and sales     <font color="blue">capabilities</font>, we will be required to employ a sales force, establish and     staff a <font color="blue">customer service</font> department, and create or identify <font color="blue">distribution</font>     channels for our drugs</td>
    </tr>
    <tr>
      <td>We <font color="blue">will <font color="blue">compete with</font></font> other companies that have     experienced and well-funded marketing and sales <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, if     we establish our own sales and <font color="blue">distribution</font> <font color="blue">capabilities</font>, we will incur     material expenses and may experience delays or have <font color="blue">difficult</font>y in gaining     <font color="blue">market <font color="blue">acceptance</font></font> for our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We currently have no marketing     <font color="blue"><font color="blue">arrangement</font>s</font> with others</td>
    </tr>
    <tr>
      <td>There can be no guarantee that, if we desire to,     we will be able to <font color="blue">enter into</font> any <font color="blue">marketing agreements on</font> favorable terms,     if at all, or that any <font color="blue">such agreements will</font> result in payments to us</td>
    </tr>
    <tr>
      <td>If we     <font color="blue">enter into</font> co-promotion or other marketing and sales <font color="blue"><font color="blue">arrangement</font>s</font> with other     companies, any revenues that we may receive will be <font color="blue">dependent on</font> the efforts     of others</td>
    </tr>
    <tr>
      <td>There can be no guarantee that these <font color="blue">efforts will</font> be successful</td>
    </tr>
    <tr>
      <td>We  may  not earn as much income as we hope due to possible changes in     <font color="blue">healthcare reimbursement policies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">continuing efforts</font> of <font color="blue">government</font> and <font color="blue">healthcare insurance companies</font>     to reduce the costs of <font color="blue">healthcare may reduce</font> the amount of income that we     can <font color="blue">generate from sales</font> of <font color="blue">future products</font>, if any</td>
    </tr>
    <tr>
      <td>For example, in certain     foreign markets, pricing and <font color="blue">profitability</font> of <font color="blue">prescription drugs</font> are subject     to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In the United States, we expect that <font color="blue">there will</font>     continue to be a number of federal and state proposals to implement similar     <font color="blue">government</font> controls</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">increasing emphasis on managed care</font> in     the <font color="blue">United States </font><font color="blue">will continue</font> to put pressure on drug <font color="blue">manufacture</font>rs to     <font color="blue">reduce prices</font></td>
    </tr>
    <tr>
      <td>Price <font color="blue">control initiatives could reduce</font> the revenue that we     receive for any products we may develop and sell in the future</td>
    </tr>
    <tr>
      <td>We have a history of losses and may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We have incurred operating <font color="blue">losses each year</font> since our inception in 1989     and  had  an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra260dtta3 million as of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We expect to incur substantial <font color="blue">losses each year</font> for at     least the next <font color="blue">several years</font> as we conduct <font color="blue"><font color="blue">clinical trial</font>s</font> of our drug     <font color="blue">candidates</font>, seek <font color="blue"><font color="blue">regulatory</font> approval</font> and continue our clinical <font color="blue">development</font>,     <font color="blue">manufacturing</font>, <font color="blue">regulatory</font> and research <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, assuming we     ultimately receive <font color="blue">approval from</font> the FDA or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>     <font color="blue">for Riquent </font>or our other drug <font color="blue">candidates</font>,                                         38       _________________________________________________________________    [92]Table of <font color="blue">Contents       </font>we will be required to develop commercial <font color="blue">manufacturing</font> <font color="blue">capabilities</font> and     marketing and <font color="blue">sales programs which may</font> result in substantial <font color="blue">additional</font>     losses</td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">profitability</font> we must, among other matters, complete the     <font color="blue">development</font> of our products, obtain all <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s and     establish commercial <font color="blue">manufacturing</font>, marketing and sales <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>The     amount  of  losses  and  the  time  required  by us to <font color="blue">reach sustained</font>     <font color="blue">profitability</font> are <font color="blue">highly uncertain</font> and we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We do not expect to generate <font color="blue">revenues from</font> the sale of Riquent, if approved,     or our other products, if any, in the near term, and we <font color="blue">may never generate</font>     <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>Our  success  in  developing and marketing our drug <font color="blue">candidates</font> depends     <font color="blue"><font color="blue">significant</font>ly</font> on our ability to obtain <font color="blue">patent protection</font> <font color="blue">for Riquent </font>and any     other developed products</td>
    </tr>
    <tr>
      <td>In addition, we will need to <font color="blue">successfully</font> preserve     our <font color="blue">trade secrets</font> and operate <font color="blue">without infringing on</font> the rights of others</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on patents</font> and other <font color="blue">unpatented <font color="blue">intellectual property</font></font> to     prevent others from improperly benefiting from products or <font color="blue">technologies</font> that     we may have developed</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we owned 105 issued patents     and 75 pending patent <font color="blue">applications</font> in the <font color="blue">United States </font>and in foreign     countries</td>
    </tr>
    <tr>
      <td>These patents and patent <font color="blue">applications</font> cover various <font color="blue">technologies</font>     and drug <font color="blue">candidates</font>, including Riquent</td>
    </tr>
    <tr>
      <td>There can be no assurance, however,     that any <font color="blue">additional</font> <font color="blue">patents will</font> be issued, that the scope of any patent     <font color="blue">protection will</font> be sufficient to <font color="blue">protect us</font> or our <font color="blue">technology</font>, or that any     current  or  future  issued  <font color="blue">patent will</font> be held valid if <font color="blue">subsequently</font>     challenged</td>
    </tr>
    <tr>
      <td>There  is  a  substantial backlog of bio<font color="blue">technology</font> patent     <font color="blue"><font color="blue">applications</font> at</font> the <font color="blue">United States </font>Patent and Trademark Office that may delay     the review and issuance of any patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of bio<font color="blue">technology</font>     firms like ours is <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font> and factual     questions, and <font color="blue">no consistent policy</font> has emerged regarding the breadth of     claims covered in bio<font color="blue">technology</font> patents or the <font color="blue">protection <font color="blue">afforded by</font></font> these     patents</td>
    </tr>
    <tr>
      <td>We intend to continue to <font color="blue">file patent <font color="blue">applications</font> as</font> believed     <font color="blue">appropriate</font> for <font color="blue">patents covering both</font> our products and processes</td>
    </tr>
    <tr>
      <td>There can     be no assurance that <font color="blue">patents will</font> be <font color="blue">issued from</font> any of these <font color="blue">applications</font>,     or that the scope of any issued <font color="blue">patents will</font> protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">necessarily</font> know if others, including <font color="blue">competitors</font>, have     patents or patent <font color="blue">applications</font> pending that relate to compounds or processes     that overlap or <font color="blue">compete with</font> our <font color="blue">intellectual property</font> or <font color="blue">which may affect</font>     our freedom to operate</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">certain families</font> of patents and     patent <font color="blue">applications</font> that contain claims covering subject matter that may     affect our ability to develop, <font color="blue">manufacture</font> and sell our products in the     future</td>
    </tr>
    <tr>
      <td>We have <font color="blue">conducted <font color="blue">investigations</font> into</font> these <font color="blue">patent families</font> to     determine  what  impact, if any, the <font color="blue">patent families</font> could have on our     continued <font color="blue">development</font>, <font color="blue">manufacture</font> and, if <font color="blue">approved by</font> the FDA, sale of our     drug <font color="blue">candidates</font>, including Riquent</td>
    </tr>
    <tr>
      <td>Based on our <font color="blue">investigations</font> to date, we     currently do not believe that these <font color="blue">patent families</font> are likely to impede the     <font color="blue">advancement</font> of our drug <font color="blue">candidates</font>, including Riquent</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that upon our <font color="blue">further investigation</font>,     these <font color="blue">patent families</font> or other <font color="blue">patents will</font> not ultimately be found to     impact the <font color="blue">advancement</font> of our drug <font color="blue">candidates</font>, including Riquent</td>
    </tr>
    <tr>
      <td>If the     <font color="blue">United States </font>Patent and Trademark Office or any <font color="blue">foreign counterpart issues</font>     or has issued patents containing <font color="blue">competitive</font> or <font color="blue">conflicting</font> claims, and if     these claims are valid, the <font color="blue">protection provided by</font> our <font color="blue">existing patents</font> or     any <font color="blue">future patents</font> that may be <font color="blue">issued could</font> be <font color="blue"><font color="blue">significant</font>ly</font> reduced, and     our ability to prevent <font color="blue">competitors</font> from developing products or <font color="blue">technologies</font>     identical or similar to ours could be <font color="blue"><font color="blue">negatively</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition,     there can be no guarantee that we would be able to obtain licenses to these     patents on <font color="blue">commercially</font> reasonable terms, if at all, or that we would be     able to develop or obtain <font color="blue">alternative</font>                                         39       _________________________________________________________________    [93]Table of <font color="blue">Contents       </font><font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain a license to a <font color="blue">technology</font> or process that     may  be  required  to develop or <font color="blue">commercialize</font> one or more of our drug     <font color="blue">candidates</font> may have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>In addition,     we may have to incur <font color="blue">significant</font> expenses and <font color="blue">management</font> time in defending     or enforcing our patents</td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">unpatented <font color="blue">intellectual property</font></font> such as <font color="blue">trade secrets</font>     and improvements, know-how, and continuing <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we seek to protect these rights, it is possible that:       •   others, including <font color="blue">competitors</font>, will develop <font color="blue">inventions relevant</font> to our     business;       •   our <font color="blue">confidentiality agreements will</font> be breached, and we may not have,     or be successful in obtaining, <font color="blue">adequate remedies</font> for such a breach; or       •   our <font color="blue">trade secrets</font> will otherwise become known or be <font color="blue">independently</font>     discovered by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial costs and devote substantial <font color="blue">management</font> time     in <font color="blue">defending suits</font> that <font color="blue">others <font color="blue">might bring</font> against us</font> for <font color="blue">infringement</font> of     <font color="blue">intellectual property</font> rights or in <font color="blue">prosecuting suits</font> that we <font color="blue">might bring</font>     <font color="blue">against others</font> to protect our <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>Because a number of companies <font color="blue">compete with</font> us, many of which have greater     resources than we do, and because we face rapid changes in <font color="blue">technology</font> in our     industry, we cannot be certain that our products will be accepted in the     marketplace or <font color="blue">capture market</font> share</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font><font color="blue">from domestic</font> and foreign bio<font color="blue">technology</font> companies, large     <font color="blue">pharmaceutical</font> companies and other <font color="blue">institutions</font> is intense and is expected     to  increase</td>
    </tr>
    <tr>
      <td>A number of companies and <font color="blue">institutions</font> are pursuing the     <font color="blue">development</font>  of  <font color="blue">pharmaceutical</font>s  in our <font color="blue">targeted areas</font></td>
    </tr>
    <tr>
      <td>Many of these     companies  are  very  large,  and have financial, technical, sales and     <font color="blue">distribution</font>  and other <font color="blue">resources substantially greater than ours</font></td>
    </tr>
    <tr>
      <td>The     greater  resources  of  these <font color="blue">competitors</font> could enable them to develop     <font color="blue">competing product</font>s more quickly than we are able to, and to market any     <font color="blue">competing product</font> more quickly or <font color="blue">effective</font>ly so as to make it extremely     <font color="blue">difficult</font> for us to develop a share of the market for our products</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">competitors</font> also include companies that are conducting <font color="blue"><font color="blue">clinical trial</font>s</font> and     pre-<font color="blue">clinical studies</font> for the treatment of lupus</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may develop     or obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for products more <font color="blue">rapidly than</font> we do</td>
    </tr>
    <tr>
      <td>If the     FDA were to approve a drug that is <font color="blue"><font color="blue">significant</font>ly</font> similar in structure to     Riquent for the same <font color="blue">indication</font> that Riquent is designed to treat, and such     drug received <font color="blue">marketing exclusivity under</font> the Orphan Drug Act, the FDA may     be  prevented  from  approving  Riquent</td>
    </tr>
    <tr>
      <td>Also,  the bio<font color="blue">technology</font> and     <font color="blue">pharmaceutical</font> industries are subject to rapid changes in <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may develop and market <font color="blue">technologies</font> and products that are more     <font color="blue">effective</font> or <font color="blue">less costly than</font> those we are developing, or that would render     our <font color="blue">technology</font> and <font color="blue">proposed products obsolete</font> or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We may not be able to take advantage of the <font color="blue">orphan drug designation</font> for     Riquent</td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2000, the FDA granted us <font color="blue">orphan drug designation</font> for     <font color="blue">Riquent  </font>for  the  treatment  of  lupus nephritis</td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">Orphan Drug Act </font>    </font><font color="blue">potentially</font>  <font color="blue">enables us</font> to obtain <font color="blue">research funding</font> and tax credits for     <font color="blue">certain research expenses</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Orphan Drug Act </font>allows for seven     years of <font color="blue">exclusive marketing rights</font> to a <font color="blue">specific drug</font> for a <font color="blue">specific orphan</font>     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td><font color="blue">Exclusivity </font>is <font color="blue">conferred upon receipt</font> of marketing <font color="blue">approval from</font>     the FDA The marketing                                         40       _________________________________________________________________    [94]Table of <font color="blue">Contents       </font><font color="blue">exclusivity prevents</font> FDA <font color="blue">approval during</font> the seven-year period of the same     drug, as defined in the FDA <font color="blue">regulations</font>, from another company for the same     orphan <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Whether we will be able to take advantage of the benefits     <font color="blue">afforded by</font> the <font color="blue">orphan drug designation</font> will ultimately be determined by the     FDA only after <font color="blue">further review</font> of our NDA     The use <font color="blue">of Riquent </font>or other <font color="blue">potential products</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, as well     as the sale of any <font color="blue">approved products</font>, may expose us to lawsuits resulting     from the use of these products</td>
    </tr>
    <tr>
      <td>The use and <font color="blue">possible sale</font> <font color="blue">of Riquent </font>or other potential <font color="blue">products may</font>     expose us to <font color="blue">legal liability</font> and <font color="blue">negative publicity</font> if we are subject to     claims that our <font color="blue">products harmed</font> people</td>
    </tr>
    <tr>
      <td>These claims might be made directly     by patients, <font color="blue">pharmaceutical</font> companies, or others</td>
    </tr>
    <tr>
      <td>We currently maintain     dlra10dtta0 million of <font color="blue">product liability insurance</font> for claims arising from the use     of our products in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">product liability insurance</font> is     becoming  <font color="blue">increasingly</font>  expensive</td>
    </tr>
    <tr>
      <td>In  addition,  in the event of any     <font color="blue">commercialization</font> of any of our products, we <font color="blue">will likely</font> need to obtain     <font color="blue">additional</font> insurance, <font color="blue">which will</font> increase our <font color="blue">insurance expenses</font></td>
    </tr>
    <tr>
      <td>There can     be no guarantee that we will be able to maintain insurance or that insurance     can be acquired at a <font color="blue">reasonable cost</font>, in <font color="blue">sufficient amount</font>s, or with broad     <font color="blue">enough coverage</font> to <font color="blue">protect us</font> against possible losses</td>
    </tr>
    <tr>
      <td>Furthermore, it is     possible that our <font color="blue">financial resources</font> would be insufficient to satisfy     <font color="blue">potential product liability</font> or other claims</td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product liability</font>     claim or series of claims brought against us could <font color="blue">negatively</font> impact our     business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue"><font color="blue">environment</font>al</font> liabilities</font> related to <font color="blue">certain <font color="blue">hazardous</font> materials</font>     used in our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Due to the nature of our <font color="blue">manufacturing</font> processes, we are subject to     <font color="blue">stringent federal</font>, state and <font color="blue">local laws governing</font> the use, handling and     disposal of <font color="blue">certain materials</font> and wastes</td>
    </tr>
    <tr>
      <td>We may have to incur <font color="blue">significant</font>     costs to <font color="blue">comply with</font> <font color="blue"><font color="blue">environment</font>al</font> <font color="blue">regulations</font> if and when our <font color="blue">manufacturing</font>     increases to <font color="blue">commercial volumes</font></td>
    </tr>
    <tr>
      <td>Current or future <font color="blue"><font color="blue">environment</font>al</font> laws may     <font color="blue"><font color="blue">significant</font>ly</font> affect our <font color="blue">operations</font> because, for instance, our production     process may be required to be altered, thereby increasing our production     costs</td>
    </tr>
    <tr>
      <td>In our research and <font color="blue">manufacturing</font> <font color="blue">activities</font>, we <font color="blue">use radioactive</font> and     other materials that could be <font color="blue">hazardous</font> to human health, safety or the     <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>These materials and <font color="blue">various wastes</font> resulting from their use are     stored  at our <font color="blue">facility</font> pending ultimate use and disposal</td>
    </tr>
    <tr>
      <td>The risk of     <font color="blue"><font color="blue">accident</font>al</font>  injury  or  <font color="blue">contamination</font>  from  these <font color="blue">materials cannot</font> be     eliminated</td>
    </tr>
    <tr>
      <td>In the event of such an <font color="blue">accident</font>, we could be held liable for     any resulting damages, and any <font color="blue">such liability could exceed</font> our resources</td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">general liability insurance</font>, we do not <font color="blue">specifically</font>     insure against <font color="blue"><font color="blue">environment</font>al</font> liabilities</td>
    </tr>
    <tr>
      <td>II RISK FACTORS RELATED SPECIFICALLY TO OUR STOCK     Our stock may be <font color="blue">removed from <font color="blue">listing on</font></font> the Nasdaq <font color="blue">quotation system</font> and may     not qualify for <font color="blue">listing on</font> any <font color="blue">stock exchange</font>, in which case it may be     <font color="blue">difficult</font> to maintain a market in our stock</td>
    </tr>
    <tr>
      <td>In 2005, we received a notice from the <font color="blue">Nasdaq Stock Market </font>that our     stock  price  fell below the required <font color="blue">minimum bid price</font></td>
    </tr>
    <tr>
      <td>We have since     <font color="blue">regained compliance with</font> the <font color="blue">minimum bid price</font> rule, but we are required to     maintain compliance in order to maintain our listing</td>
    </tr>
    <tr>
      <td>In addition to the     <font color="blue">minimum bid price</font> rule, the <font color="blue">Nasdaq Stock Market </font>has several other continued     listing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Failure to maintain compliance with <font color="blue">any Nasdaq </font>listing     <font color="blue">requirement could</font> cause our stock to be <font color="blue">removed from <font color="blue">listing on</font></font> Nasdaq</td>
    </tr>
    <tr>
      <td>If     this were to happen, we may not be able to secure <font color="blue">listing on</font> other exchanges     or <font color="blue">quotation system</font>s</td>
    </tr>
    <tr>
      <td>If our stock is <font color="blue">no longer traded on</font> an exchange or     <font color="blue">quotation system</font>, it may be <font color="blue">difficult</font> for our <font color="blue">stockholders</font> to sell the     shares that they own</td>
    </tr>
    <tr>
      <td>41       _________________________________________________________________    [95]Table of <font color="blue">Contents       </font>The ownership of our <font color="blue">common stock</font> is <font color="blue">concentrated</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of February </font>22, 2006, our three largest <font color="blue">stockholders</font> beneficially     owned <font color="blue">approximately</font> 46prca of our <font color="blue">currently outstanding shares</font> of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>who purchase our <font color="blue">common stock</font> may be subject to certain risks due     to the <font color="blue">concentrated</font> ownership of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example, the sale by     any  of  our  large  <font color="blue">stockholders</font>  of  a  <font color="blue">significant</font>  portion of that     stockholder’s holdings could have a material adverse effect on the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, two of these <font color="blue">stockholders</font> have the     ability, either alone or jointly, to <font color="blue">appoint four members</font> of our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Accordingly, these <font color="blue">stockholders</font>, either directly or <font color="blue">indirectly</font>,     have the ability to <font color="blue"><font color="blue">significant</font>ly</font> influence the outcome of all matters     submitted to a vote of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> price is volatile and <font color="blue">may decline even</font> if our business is     doing well</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been and is likely to continue     to be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">corporate events</font> have caused our stock price     to be <font color="blue">particularly</font> volatile</td>
    </tr>
    <tr>
      <td>Market prices for securities of bio<font color="blue">technology</font>     and <font color="blue">pharmaceutical</font> companies, including ours, have <font color="blue">historically been highly</font>     volatile, and the market has from time to time experienced <font color="blue">significant</font> price     and <font color="blue">volume fluctuations</font> that are unrelated to the operating performance of     particular  companies</td>
    </tr>
    <tr>
      <td>The following factors, among others, can have a     <font color="blue">significant</font> effect on the <font color="blue">market price</font> of our securities:       •   our <font color="blue">clinical trial</font> results;       •   actions or <font color="blue">decisions by</font> the FDA and other <font color="blue">comparable agencies</font>;       •   <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or new <font color="blue">therapeutic</font> products     by us or others;       •   <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights</font>;       •   public concern as to the safety of <font color="blue">drugs discovered</font> or developed by us     or others;       •   <font color="blue">future sales</font> of <font color="blue">significant</font> amounts of our <font color="blue">common stock</font> by us or our     <font color="blue">stockholders</font>;       •   <font color="blue">development</font>s concerning potential agreements with collaborators;       •   <font color="blue">comments by securities analysts</font> and <font color="blue">general market conditions</font>; and       •   <font color="blue">government</font> regulation, including any <font color="blue">legislation</font> that may impact the     price of any <font color="blue">commercial products</font> that we may seek to sell</td>
    </tr>
    <tr>
      <td>The <font color="blue">realization</font> of any of the <font color="blue">risks described</font> in these “Risk Factors”     could have a negative effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>42       _________________________________________________________________    [96]Table of <font color="blue">Contents       </font>Future sales of our stock by our <font color="blue">stockholders</font> could <font color="blue">negatively</font> affect the     <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that     <font color="blue">such sales could</font> occur, could result in a drop in the <font color="blue">market price</font> of our     securities</td>
    </tr>
    <tr>
      <td><font color="blue">As of February </font>22, 2006, there were:       •   <font color="blue">Approximately </font>32cmam523cmam381 shares of <font color="blue">common stock</font> that have <font color="blue">been issued</font>     in <font color="blue">registered offerings</font> or were <font color="blue">otherwise freely tradable</font> in the public     markets</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Approximately </font>11cmam144 shares of <font color="blue">common stock</font> eligible for resale in the     <font color="blue">public market</font> pursuant to SEC Rule 144</td>
    </tr>
    <tr>
      <td>•   4cmam399cmam992 shares of <font color="blue">common stock</font> underlying warrants which have been     registered for <font color="blue">resale under</font> a <font color="blue">Registration Statement </font>on Form S-3</td>
    </tr>
    <tr>
      <td>•   2cmam194cmam171 shares of <font color="blue">common stock</font> that may be issued on the exercise of     <font color="blue">outstanding stock options granted under</font> our <font color="blue">various stock option</font> plans at a     <font color="blue">weighted average exercise price</font> of dlra15dtta23 per share</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Approximately </font>3cmam271cmam281 shares of <font color="blue">common stock</font> reserved for future     <font color="blue">issuance pursuant</font> to <font color="blue">awards granted under</font> our <font color="blue">equity incentive</font> and employee     <font color="blue">stock purchase</font> plans, <font color="blue">which shares</font> are covered by <font color="blue">effective</font> registration     <font color="blue">statements under</font> the <font color="blue">Securities Act </font>of 1933, as amended (the “Securities     Act”)</td>
    </tr>
    <tr>
      <td>•   Pursuant to a <font color="blue">registration statement on</font> Form S-3 filed on <font color="blue">December </font>10,     2002, we registered an <font color="blue">aggregate amount</font> of dlra125cmam000cmam000 of our <font color="blue">common stock</font>     for <font color="blue">issuance from</font> time to time</td>
    </tr>
    <tr>
      <td><font color="blue">As of February </font>22, 2006, there was     dlra53cmam937cmam500 of our <font color="blue">common stock</font> available for <font color="blue">future issuance</font></td>
    </tr>
    <tr>
      <td>We  cannot estimate the number of shares of <font color="blue">common stock</font> that may     actually be resold in the <font color="blue">public market</font> because this <font color="blue">will depend on</font> the     <font color="blue">market price</font> for our <font color="blue">common stock</font>, the individual <font color="blue">circumstances</font> of the     sellers and other factors</td>
    </tr>
    <tr>
      <td>We also have a number of <font color="blue">stockholders</font> that own     <font color="blue">significant</font>  blocks  of  our  <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">stockholders</font> sell     <font color="blue">significant</font> portions of their holdings in a <font color="blue">relatively</font> short time, for     liquidity or other reasons, the <font color="blue">market price</font> of our <font color="blue">common stock</font> could drop     <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain <font color="blue">effective</font> internal controls in <font color="blue">accordance</font>     with Section 404 of the Sarbanes-Oxley Act could have a material adverse     effect on our business and stock price</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act requires us to <font color="blue">evaluate annually</font>     the <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting as of     the end of <font color="blue">each <font color="blue">fiscal year</font> beginning</font> in 2004 and to include a <font color="blue">management</font>     report assessing the <font color="blue">effective</font>ness of our <font color="blue"><font color="blue">internal controls over</font> financial</font>     reporting in all annual reports <font color="blue">beginning with</font> the annual report on <font color="blue">Form     </font>10-K for the <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>Section 404 also requires     our <font color="blue">independent registered public accounting firm</font> to attest to, and report     on,  <font color="blue">management</font>’s  <font color="blue">assessment</font>  of our <font color="blue"><font color="blue">internal controls over</font> financial</font>     reporting</td>
    </tr>
    <tr>
      <td>We evaluated our <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting as of     <font color="blue">December </font>31, 2005 in order to <font color="blue">comply with</font> Section 404 and concluded that our     <font color="blue">disclosure</font>  controls and procedures were <font color="blue">effective</font> as of such date</td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">independent registered public accounting firm</font> reported on our     assertion <font color="blue">with respect</font> to the <font color="blue">effective</font>ness of our <font color="blue">internal controls over</font>     financial reporting as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If we fail to maintain the     adequacy  of  our  internal  controls, as such standards are modified,     supplemented or <font color="blue">amended from</font> time to                                         43       _________________________________________________________________    [97]Table of <font color="blue">Contents       </font>time, we <font color="blue">cannot provide</font> any assurances that we will be able to conclude in     the future that we have <font color="blue">effective</font> <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting     in <font color="blue">accordance</font> with Section 404</td>
    </tr>
    <tr>
      <td>Anti-takeover <font color="blue">devices may prevent</font> changes in our board of <font color="blue">directors</font> and     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We have in place several anti-takeover devices, including a stockholder     rights plan, which may have the effect of delaying or preventing changes in     our  <font color="blue">management</font>  or  deterring  third  <font color="blue">parties from seeking</font> to acquire     <font color="blue">significant</font> positions in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example, one anti-takeover     device  provides for a board of <font color="blue">directors</font> that is <font color="blue">separated into three</font>     classes, with their terms in <font color="blue">office staggered over three year periods</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>has the effect of delaying a change in control of our board of <font color="blue">directors</font>     without the <font color="blue">cooperation</font> of the <font color="blue">incumbent board</font></td>
    </tr>
    <tr>
      <td>In addition, our bylaws     require <font color="blue">stockholders</font> to <font color="blue">give us written</font> notice of any proposal or director     <font color="blue">nomination within</font> a <font color="blue">specified period</font> of time prior to the <font color="blue">annual stockholder</font>     meeting, establish certain qualifications for a person to be elected or     appointed to the board of <font color="blue">directors</font> during the pendency of certain business     <font color="blue">combination</font> transactions, and do not allow <font color="blue">stockholders</font> to call a special     meeting of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also issue shares</font> of <font color="blue">preferred stock without further stockholder</font>     approval and upon terms that our board of <font color="blue">directors</font> may determine in the     future</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock could</font> have the effect of making it     more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our outstanding     stock, and the holders of such <font color="blue">preferred stock could</font> have voting, dividend,     <font color="blue">liquidation</font> and other rights superior to those of holders of our common     stock</td>
    </tr>
  </tbody>
</table>